You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Recurrent Endometrial Cancer

DEL CARMEN, MARCELA G. MD, MPH; BORUTA, DAVID M. II MD; SCHORGE, JOHN O. MD

Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e318218c6d1
Endometrial Cancer
Abstract

Endometrial cancer is the most common gynecologic malignancy in the United States. The majority of women are diagnosed with early-stage, low-grade endometrioid tumors that are highly curable with primary surgery. Patients with more advanced and/or higher grade disease require multimodality therapy and have a higher risk for recurrence. Although uterine papillary serous carcinoma and clear cell carcinoma are diagnosed infrequently, they account for almost half of all relapses. As women with recurrent endometrial cancer constitute a heterogeneous group, an individualized approach is required. We review the treatment options of surgery, radiation, hormonal therapy, cytotoxic chemotherapy, and biological agents.

Author Information

Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Supported by none.

Correspondence: John O. Schorge, MD, Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Yawkey 9 E, Boston, MA. e-mail: jschorge@partners.org

© 2011 Lippincott Williams & Wilkins, Inc.